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Intermittent psychological stress was induced in adult rats by 2 h/day
of immobilization stress for 4 days, with or without blocking the
function of IL-6 by using an anti-IL-6 antibody. Basal concentrations
of serum corticosterone, IL-1, IL-6, and TNF- were assessed 24 h
after the last intervention, as were levels of glucocorticoid receptors
(GR) and activities of glucocorticoid-inducible enzymes (tyrosine
aminotransferase and glutamine synthetase) in muscle and liver.
Whole blood cultures were used to assess both spontaneous and
LPS-induced reactivity of peripheral blood mononuclear cells. Stress
increased corticosterone concentration in a manner partially modu-
lated by IL-6. Serum IL-1 concentration was downregulated during
stress when IL-6 was blocked (P  0.01). LPS-induced IL-6 secretion
by peripheral blood mononuclear cells in vitro correlated positively
with serum IL-1 concentration in antibody-treated groups, indepen-
dently of stress (R 0.70 in nonstressed and R 0.78 in stressed rats;
both P  0.05), whereas serum corticosterone concentration corre-
lated positively with LPS-induced secretion of IL-6 only in control
rats (R  0.66; P  0.05). Reductions in liver GR levels indicated
independent effects of stress (34.5%) and anti-IL-6 antibody (16.7%)
and additive effects for both (62.5%). Similar results are reported for
vastus muscle. Conversely, stress increased tyrosine aminotransferase
and glutamine synthetase activities in muscle and liver with a signif-
icant (P  0.05) effect of anti-IL-6 antibody only seen in stressed
livers. In conclusion, IL-6 plays a role in maintaining circulating
IL-1 concentration after multiple exposures to stress, thus promoting
a continued elevation of corticosterone release; in peripheral tissues,
IL-6 antagonizes the effects of glucocorticoids, especially at the level
of GR concentration.
corticosterone; glucocorticoid receptors; tyrosine aminotransferase;
peripheral blood mononuclear cell function
ACUTE PSYCHOLOGICAL STRESS is known to activate the hypotha-
lamic-pituitary-adrenal (HPA) axis, resulting in transiently in-
creased release of inflammatory cytokines (28) and glucocorti-
coids (45). In contrast, multiple exposures to stress lead to adap-
tive responses in target tissues such as liver, skeletal muscle, and
immune cells. These responses may be influenced by the severity
of the stressor and the duration of the stress exposure. The
endocrine and cytokine responses are known to be interrelated but
are complex and still incompletely understood.
Human subjects with chronic mild psychological stress can
be divided into those with low cortisol responses to stress
(nonresponders) and those with high cortisol responses to
stress (responders) (33). Serum IL-6 concentration is higher in
the nonresponders, illustrating the role of cortisol as a negative
feedback mechanism to prevent an “overshoot” of the inflam-
matory response to stress, as was suggested in earlier reviews
(45, 46). On the other hand, several experiments have high-
lighted the role of IL-6 as a stimulator of cortisol release by
either directly acting on the adrenal gland (19, 52) or by
upstream stimulation of the HPA axis (40, 72). Similarly, IL-6
is associated with greater bioavailability of cortisol via inhibi-
tion of cortisol-binding globulin synthesis (7). These results
suggest a central role for IL-6 in the bidirectional communi-
cation between the cytokine and glucocorticoid systems in
response to stress.
Although it is clear from the above that both cytokines and
glucocorticoids are important links in the HPA axis response,
the exact mechanisms and role players in the adaptive re-
sponses of the target tissues to multiple stress exposures are
less clear.
The immune cell responses to stress differ between acute
and chronic exposure. Acute social stress in rats was previ-
ously shown to depress T cell count after 2 h and to a lesser
extent after 48 h of constant stress exposure (63). Also, the in
vitro mitogen-induced T cell proliferative response followed
the same pattern and was depressed after 2 h but not after 48 h
of stress (63). However, an even longer exposure to stress
(6 wk) impaired T cell-dependent antibody production in a
murine model of chronic mild depression (61). The changes in
T cell functional capacity reported in the above-mentioned
study were not related to the circulating glucocorticoid con-
centration, which remained unchanged at the time points mea-
sured (61). This suggests either an increase in T cell sensitivity
to stress hormones or an alternative mechanism.
Apart from their regulatory roles in the immune response,
both glucocorticoids and IL-6 have been shown to have met-
abolic roles. Metabolic effects of glucocorticoids include, for
example, the upregulation of gluconeogenesis via glucocorti-
coid-inducible enzymes such as glutamine synthetase (GS) and
tyrosine aminotransferase (TAT), which have been shown to
have increased activities in liver during stress (35, 50) and may
therefore serve as downstream indicators of glucocorticoid
action.
The biological effect of cortisol is mediated by the glucocor-
ticoid receptor (GR) (37). Glucocorticoids can themselves
regulate levels of GR (1). However, the exact effect of stress on
GR levels is controversial. Some research groups reported
decreased GR levels in response to increased circulating cor-
tisol (21, 70), suggesting a mechanism to limit the prolonged
effects of cortisol, whereas others reported increases in both
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the levels and activity of GR (2, 66). Given the importance of
GR in the regulation of glucocorticoid action, this discrepancy
warrants further investigation. Furthermore, NF-B-mediated
inflammation was recently reported to induce target tissue
resistance to glucocorticoids by altering GR activity in the
lungs (41), indicating interaction between mediators of inflam-
mation and glucocorticoid action.
IL-6 has a known metabolic role in response to the stress of
exercise (54), and a number of studies suggest that a bidirec-
tional communication between IL-6 and glucocorticoids in
peripheral tissues is possible, although results reported are
varied. On the one hand, IL-6 enhanced glucocorticoid action,
e.g., by upregulation of GR in lymphoid and osteoblast-like
cell lines (3, 13, 56) and by increasing release of the acute
phase proteins [haptoglobin (31) and 2-macroglobulin
(26, 34)] in hepatoma cells. On the other hand, a series of in
vivo (25, 64) and in vitro (24, 65) studies elucidated an
antiglucocorticoid effect of IL-6. In adrenalectomized rats
exposed to endotoxin treatment (elevating IL-6), dexametha-
sone-induced phosphoenolpyruvate carboxykinase activity was
decreased. This was found to be the result of IL-6-mediated
downregulation of hepatic GR.
Taking the above results into consideration, the modulation
by IL-6 of glucocorticoid-induced responses occurs in many
tissues and could be either repressing or enhancing the effect of
the glucocorticoids. Alternatively, no cross-talk occurs, but
IL-6 may have independent additive effects. The potential
benefit of upregulating glucocorticoid-induced responses would
be to inhibit inflammation, whereas a potential benefit of down-
regulation of glucocorticoid-induced responses would be to
inhibit catabolic metabolism. Therefore, we hypothesize that
the glucocorticoid-induced upregulation of metabolic genes
would be moderated by IL-6 to prevent excessive catabolism,
whereas the modulatory effect of IL-6 on the adrenal secretion
of corticosterone would be additive to further promote an
anti-inflammatory response.
Recently, the possibility of blocking the effects of one or
another cytokine in the cascade of the inflammatory response
has become possible by either the use of knockout models, e.g.,
an IL-6 knockout mouse model (71), or administration of
antiserum or antibody, e.g., antibodies directed against IL-6
(39, 49). Such studies, although not close to in vivo physio-
logical models of imposed stress, can illuminate our under-
standing of the major role players in these complex responses
to stress or illness.
In a rat model of meningitis, treatment with anti-IL-6 anti-
bodies resulted in a decreased immune response to the disease
[fewer white blood cells (WBCs) in cerebrospinal fluid] (39),
indicating a direct role for IL-6 in upregulation of WBC
proliferation. In IL-6 knockout mice, TNF- concentrations
were higher after experimental endotoxemia (LPS injections)
than in IL-6 intact mice (71). Because IL-1 is the primary
stimulus for TNF- production and is also known to be
upstream of IL-6 secretion, this led to the conclusion that IL-6
normally limits the upregulation of TNF- and possibly other
proinflammatory cytokines. However, in the absence of other
circulating immune and stress-endocrine measurements, the
significance of this result is difficult to interpret.
Therefore, the aims of this study were to induce a condition
of mild psychological stress in rats by multiple exposures to
immobilization stress, while blocking the function of IL-6, to
determine 1) the effect of IL-6 on circulating concentrations of
other proinflammatory cytokines in response to stress, 2) the
effect of IL-6 on circulating glucocorticoid concentration, and
3) differences between IL-6-mediated modulation of stress-
induced adaptive responses in target tissues (GR levels and
activities of glucocorticoid-inducible enzymes in both liver and
skeletal muscle and in vitro functional capacity of proinflam-
matory immune cells). To assess residual effects remaining
evident at basal, nonacute time points, rats were killed 24 h
after the final stressor.
MATERIALS AND METHODS
Experimental Animals
Forty male Wistar rats were used in this study. Rats were housed in
standard rat cages and fed rat chow and tap water ad libitum.
Temperature in the housing facility was controlled at 21°C, and lights
were set to a 12:12-h light-dark cycle (lights on at 7:00 AM). Rats
were bought in from a breeding facility and allowed 3 wk to acclimate
before initiation of the study protocol, during which time they were
handled and weighed once per day (7 times per wk) to accustom them
to this procedure. The investigation conforms with the “Guide for the
Care and Use of Laboratory Animals” published by the National
Institutes of Health (NIH publication 85-23, revised 1996), and the
study was approved by the Stellenbosch University Ethics Review
Board.
Preparation of Anti-IL-6 Antibody Treatments
An antibody raised in goats immunized with purified Escherichia
coli-derived recombinant rat IL-6 (AF506, R&D Systems) was used
as intervention treatment in this study. Lyophilized antibody (100 g)
was reconstituted with 1 ml of sterile PBS, according to manufactur-
er’s instructions, to yield an antibody concentration of 0.1 mg/ml. This
stock solution was further diluted in sterile PBS to yield a final
concentration of 2 g/ml, so that an injection of 0.5 ml/day would
result in a dose of 1 g  rat1 day1 of anti-IL-6 antibody, in
accordance with the manufacturer’s indicated neutralization dosage,
as well as with previous studies (6, 27). This solution was kept at 4°C
for the duration of the protocol (stable for 1 mo at this temperature,
according to the manufacturer).
Intervention
Rats were divided into four experimental groups (n  10 each):
control  placebo (CP), control  antibody (CA), immobilization 
placebo (IP), and immobilization  antibody (IA). Placebo rats (CP
and IP) were injected intraperitoneally with 0.5 ml of sterile isotonic
saline once per day, and antibody rats (CA and IA) were injected
intraperitoneally with 0.5 ml of anti-IL-6 antibody, prepared as
described above. In addition, immobilization groups (IP and IA) were
subjected to immobilization stress for 2 h once per day, using the
protocol described previously (62). Briefly, rats were individually
confined in small Perspex cages (6 	 8 	 18 cm) designed for this
purpose, which did not allow free movement. Both the injection
treatment and immobilization stress protocols lasted 4 days, after
which rats were killed by decapitation 24 h after the last intervention
procedure, to exclude the acute response to the last intervention from
being a confounding factor.
Sample Collection
Whole blood was collected by exsanguination, via a heparinized
funnel, into one lithium heparin and one serum separation tube (SST)
Vacutainer tube (BD Systems, Plymouth, UK). The heparinized blood
was analyzed for total and differential WBC counts and mitogen-
induced peripheral blood mononuclear cells (PBMC) IL-6 secretion in
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vitro. SST blood was centrifuged at 3,000 rpm for 10 min at 0°C,
before being aliquoted and frozen at 80°C for subsequent batch
analysis of IL-1, TNF-, IL-6, and corticosterone concentrations.
In addition, skeletal muscle (gastrocnemius and vastus) and livers
were dissected out within 5 min of decapitation. All samples were
snap-frozen in liquid nitrogen and then stored at 80°C until subse-
quent analysis for GR level and GS and TAT activities.
Blood Analysis
All analyses on fresh blood were performed within 3 h of collec-
tion. Heparinized blood (500 l) was decanted immediately into a
1.5-ml reaction vial (Eppendorf; Sigma) for determination of a total
and differential WBC count, performed by automated analysis in a
professional veterinary pathology laboratory (VetCare, Parow, South
Africa). The rest of the blood was used to determine the ability of
PBMCs in whole blood culture to secrete IL-6 in response to mitogen
(E. coli LPS) stimulation, using an adaptation of a method used
previously for investigations in human blood (55). Briefly, whole
blood (500 l) was incubated in 2 ml of RPMI 1640 medium
(Highveld Biologicals) in one tube and in 2 ml of RPMI 1640 medium
containing E. coli LPS (1.5 g/l) in another tube for 24 h. All samples
were then centrifuged, and the supernatant was used for determination
of IL-6 concentration by ELISA (Biotrak RPN 2742; AEC Amersham
Biosciences). IL-6 concentration measured in the tube containing
sample and medium only, was termed “spontaneous IL-6 secretion,”
whereas the difference between IL-6 concentration in the LPS-con-
taining tube and the spontaneous IL-6 secretion was termed “LPS-
induced IL-6 secretion.”
Commercially available ELISA kits were used for determination of
serum IL-1 (Biotrak RPN 2743; AEC Amersham Biosciences),
TNF- (865.000.096; Diaclone), IL-6 (Biotrak RPN 2742; AEC
Amersham Biosciences), and corticosterone (AC-14F1, Octeia; Im-
munodiagnostic Systems) concentrations.
Determination of Muscle and Liver GR Levels by Binding Assay
Liver and vastus muscle cytosols were prepared from homogenates
with the use of modifications of the method previously described
(2, 29, 67). Briefly, to prepare liver cytosol, the same areas of each of
the livers were thawed, weighed, cut into fine pieces, and homoge-
nized (using an Ultra-turrax homogenizer) in cytosol buffer A (10 mM
Tris HCl, pH 7.5, containing 0.25 M sucrose, 0.1 mM PMSF, and 10
g/ml aprotinin) at 4°C and at a tissue-to-buffer ratio of 1:2 (wt/vol),
e.g., 1 g of tissue was homogenized in 2 ml of buffer. The homogenate
was ultracentrifuged at 100,000 g for 1 h at 4°C. The upper fatty layer
was discarded, and the crude cytosol was treated with 100 l of
dextran-coated charcoal (DCC; 3.75 g of charcoal and 0.375 g of
dextran T-70 made up in 100 ml of 10 mM Tris HCl, pH 7.5) for 15
min at 4°C to remove endogenous steroids. This was followed by a
centrifugation step (3,000 rpm for 10 min at 4°C). The resulting clear
supernatant was referred to as “liver cytosol.” “Muscle cytosol” was
prepared from both vastus muscles in a similar fashion to preparation
of the liver cytosol, except that the cytosol buffer A was replaced with
cytosol buffer B (10 mM Tris HCl, pH 7.5, which contained 0.25 M
sucrose, 1.5 mM EDTA, 10 mM sodium molybdate, 5 mM DTT, 10
mM monothioglycerol, 2 mM PMSF, 10 g/ml leupeptin, and 10
g/ml aprotinin). The protein concentration of the cytosols was
determined by the Bradford assay (9).
Liver cytosols were diluted 1:20 in cytosol buffer A, whereas
muscle cytosols were used undiluted in the binding assay. To deter-
mine GR binding capacity, cytosol (250 l) was incubated with 10 l
of 400 nM [3H]dexamethasone (diluted in ethanol), in the presence of
10 l excess (0.4 mM) unlabeled dexamethasone (nonspecific recep-
tor binding) or ethanol (total receptor binding) and 130 l of cytosol
buffer (buffer A for liver and buffer B for muscle) for 24 h at 4°C.
DCC (100 l) was added for 10 min at 4°C to separate free and
GR-bound [3H]dexamethasone (90 Ci/mmol; Amersham Biosciences,
Athens, Greece) as previously described (8). DCC-containing samples
were then centrifuged at 3,000 g for 10 min at 4°C. The supernatants
(350 l) were collected into scintillation vials, 3 ml of scintillation
fluid (catalog no. 1004000; Zinsser Analytical) were added, and
radioactivity was measured using a Beckman LS3801 scintillation
counter. Specific receptor binding was determined as the difference
between total receptor binding and nonspecific receptor binding.
Specific receptor binding was normalized for protein content (ex-
pressed as fmol/mg protein). DCC efficiency for removal of unbound
radioactive-labeled steroid was at least 95%, and counting efficiency
was typically 35% or higher, with 10% ligand depletion.
Tyrosine Aminotransferase Assay
Liver and muscle cytosols were prepared as for the binding assay.
Liver cytosols were diluted 1:100 in K2HPO4 buffer (125 mM)
containing 5 mg/ml BSA, 1 mM EDTA, and 1 mM DTT, but muscle
cytosols were used undiluted. TAT activity was determined according
to a method described previously (12, 20, 60). In short, TAT catalyzes
the conversion of tyrosine to p-hydroxyphenylpyruvate (pHPP) in the
presence of -ketoglutarate and pyridoxal-5
-phosphate. After incu-
bation periods of 5, 10, 20, and 30 min at 37°C, 10 N KOH was added
to catalyze the conversion of pHPP to oxalate and p-hydroxybenzal-
dehyde (pHBA). After 30 min, the formation of pHBA was quantified
spectrophotometrically by measurement of absorbance at 330 nm.
TAT activity was calculated by using a molar extinction coefficient of
19,900 M1 cm1 for pHBA (12). One unit of enzyme activity was
defined as the quantity of enzyme that catalyzed the formation of 1
mmol of pHPP per minute at 37°C and was expressed relative to
cytosol protein content.
GS Assay
GS activity was determined in cytosols from gastrocnemius muscle
samples with a method described earlier (42, 43), which measures the
GS-dependent formation from glutamine of -glutamyl hydroxamate,
quantified spectrophotometrically by measurement of absorbance at
540 nm after 25 min of incubation at 37°C. GS activity was calculated
with a molar extinction coefficient of 1.08 M/cm (44) and was
expressed relative to cytosol protein content.
Statistical Analysis
Effects of interventions were assessed by two-way ANOVA (con-
trol vs. immobilization and placebo vs. antibody), and differences
between experimental groups were determined with Fisher’s post hoc
tests. Correlations between parameters measured were determined by
Pearson’s correlations (Statistica version 7; StatSoft). The level of
significance was set at P  0.05.
RESULTS
Body Mass
Average percent change in body mass was calculated for
days 1–4 before the start of the intervention protocol, as well
as for the 4 days of the intervention protocol (Fig. 1). Average
percent change in body mass was similar in all groups during
the 4 days before entry into the study, and groups had similar
average body masses on day 1 of the intervention protocol
(means SE; CP: 519 18, CA: 509 10, IP: 517 15, and
IA: 498  22 g). There was a main effect of stress on body
mass (P  0.00001). Both groups subjected to immobilization
stress (IP and IA) lost a significantly greater percent body mass
during the intervention protocol than their respective non-
stressed groups (CP and CA) (Fig. 1). When comparing the two
immobilized groups (IP and IA), there was no significant
main effect of anti-IL-6 antibody treatment on the percent
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change in body mass from day 1 of the stress intervention to
death (P  0.08).
Responses Measured in Circulation
Mean corticosterone concentration was significantly higher
in IP vs. both CP and CA (Fig. 2). Although this increase
tended to be ameliorated in IA, mean corticosterone concen-
tration of IA was not significantly different from any other
group.
IL-6 concentration was below the detectable level in all but
four samples, and TNF- was detectable in only two (different)
samples. IL-1 concentration decreased during stress (Fig. 3)
but only significantly so when the IL-6 antibody was admin-
istered.
Target Tissue Responses
PBMC functional response. Total and differential WBC
counts were similar for all experimental groups (Table 1).
Although spontaneous in vitro IL-6 release by PBMCs was not
influenced by the study protocol (Fig. 4A), treatment with
anti-IL-6 antibody was associated with significantly increased
LPS-induced IL-6 release from PBMCs after 24 h of incuba-
tion (Fig. 4B). Although the treatment effect was significant,
post hoc analysis indicated a more robust difference in non-
stressed groups, for both absolute LPS-induced IL-6 release
(Fig. 4B) and IL-6 release expressed relative to PBMC count
(CP: 31.0  8.1, CA: 72.4  16.1, IP: 31.8  16.9, IA: 47.6 
15.8 pg/cell 	 106).
LPS-induced IL-6 secretion in vitro was positively corre-
lated with serum IL-1 concentration in both antibody-treated
groups (Table 2). Although serum corticosterone concentration
was positively correlated with LPS-induced secretion of IL-6
in CP, this relationship was lost after intervention with anti-
body, immobilization, or both (Table 2).
Metabolic tissue parameters. GR levels in both vastus mus-
cle and liver were significantly downregulated in response to
stress (Fig. 5). In addition, treatment with anti-IL-6 antibody
significantly decreased GR levels in control and stressed ani-
mals. TAT activity was significantly upregulated in both the
vastus muscle and liver in the stressed groups compared with
controls (Fig. 6). Furthermore, TAT activity was higher in the
antibody-treated groups than in the corresponding placebo
groups, although only significantly so for the stressed group in
the liver (Fig. 6). Although GS activity did not seem to be
significantly influenced by anti-IL-6 antibody treatment, stress
Fig. 1. Mean percent change in body mass for 4 days before the start of the
intervention protocol vs. during the 4 days of the intervention protocol. Values
are means  SE. CP, control  placebo treated; CA, control  anti-IL-6
antibody treated; IP, immobilized  placebo treated; IA, immobilized 
anti-IL-6 treated. P values were obtained with Fisher’s post hoc analysis.
Fig. 2. Differences in serum corticosterone concentration between experimen-
tal groups. Values are means  SE. P values were obtained with Fisher’s post
hoc analysis.
Fig. 3. Effect of anti-IL-6 treatment and/or immobilization stress on serum
IL-1 concentrations. Values are means  SE. P values were obtained with
Fisher’s post hoc analysis.
Table 1. Total and differential WBC counts at death
Parameter CP CA IP IA
WBCs, 	109/l 8.40.8 9.80.4 8.40.6 7.80.4
Neutrophils, 	109/l 0.80.2 0.90.2 0.70.1 1.00.3
Lymphocytes,
	109/l 7.20.7 8.60.5 7.30.6 6.60.5
Monocytes, 	109/l 0.150.07 0.150.05 0.150.06 0.100.05
Values are means  SE. CP, control  placebo; CA, control  placebo
treated; IP, immobilized  placebo treated; IA, immobilized  anti-IL-6
treated; WBC, white blood cell. P values were obtained with Fisher’s post hoc
analysis.
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resulted in significantly increased GS activity in gastrocnemius
muscle (Fig. 7).
DISCUSSION
No in vivo studies have investigated the effect of multiple
exposures to psychological stress on cytokines in conjunction
with endocrine parameters and with inclusion of GR analysis at
the level of target tissues other than the central nervous system.
The present study utilized two treatments (namely, anti-IL-6
antibody and multiple exposures to immobilization) to clearly
define four conditions: no intervention, an effect of absence of
IL-6 alone, an effect of stress with an adequate capacity for an
IL-6 response, and an effect of absence of IL-6 in the presence
of stress. Together, these data illuminate the role of IL-6 under
basal unstressed conditions and in the presence of psycholog-
ical stress.
Circulating Parameters
Similar to earlier results by our group and other research
groups (14, 45, 62), repeated exposures to immobilization
stress resulted in significantly increased basal serum cortico-
sterone concentrations compared with control groups. How-
ever, a novel finding is that, in the IL-6-antibody-treated
stressed group, this increase was attenuated (Fig. 2). These
results suggest that the full-blown corticosterone response is
dependent, at least in part, on IL-6 during multiple exposures
to stress. These results are in agreement with studies reporting
a stimulatory effect of IL-6 on the HPA axis at different levels,
including the pituitary and adrenal glands, which results in an
increased corticosterone secretion (36, 47, 72). However, the
Fig. 4. Effect of in vivo anti-IL-6 treatment on spontaneous (A) and mitogen-
induced (B) secretion of IL-6 by peripheral blood mononuclear cells in
plasma-replaced blood culture, after 24 h of incubation. Values are means 
SE. P values were obtained with Fisher’s post hoc analysis.
Table 2. Correlations between LPS-induced IL-6
secretion by PBMCs in culture and serum IL-1
and corticosterone concentration
CP CA IP IA
Serum IL-1 concentration, pg/l
vs. LPS-induced IL-6, pg/ml 0.18 0.70* 0.07 0.78*
Serum corticosterone concentration, ng/ml
vs. LPS-induced IL-6, pg/ml 0.66* 0.49 0.12 0.14
Values are R values. PBMCs, peripheral blood mononuclear cells. *P  0.05.
Fig. 5. Effects of immobilization stress and anti-IL-6 antibody treatment on
glucocorticoid receptor (GR) levels (as determined by binding assay) in vastus
muscle (A) and liver (B) of male Wistar rats. Values are means  SE. P values
were obtained with Fisher’s post hoc analysis.
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results of the present study are not in agreement with a
previous study utilizing anti-IL-6-treated mice, which sug-
gested that acute restraint stress activates the HPA axis inde-
pendently of IL-6 (49). There may have been a few factors that
differed between their study and the present one, for example,
a much higher basal corticosterone concentration even in their
control group, varied individual corticosterone responses in
their stressed groups, and small sample size.
Circulating corticosterone provides negative feedback to
attenuate IL-1 secretion (28). The negative feedback provided
by the elevated corticosterone concentrations in IP in the
present study (Fig. 2) appeared to be sufficient in these rats for
their IL-1 concentrations to be similar to their controls (CP)
under basal conditions despite prior exposures to stress (Fig. 3). A
novel finding in the present study was that blocking of IL-6 is
associated with a significant decrease in IL-1 under basal
conditions only in the stressed group (Fig. 3). This finding was
unexpected because the corticosterone levels in IA were less
elevated at the time of death than that for IP (Fig. 2) so that less
negative feedback might have been expected. One explanation
for this finding is that the system in IA is lacking an agent that
normally promotes IL-1 secretion. We therefore suggest that
positive feedback by IL-6 on IL-1 secretion occurs with stress
and that the role is to partially negate the downregulatory effect
of corticosterone on IL-1. This suggestion is supported by an
earlier in vitro finding of IL-6-stimulated upregulation of IL-1
mRNA in human T cells (51). However, because this sugges-
tion is based in part on the assumption of transiently elevated
IL-6, which was no longer evident under the basal conditions
at death, it can only be proven definitively in vivo, by assess-
ment of multiple time points after an acute stressor when IL-6
will also be sufficiently elevated to be easily detectable. None-
theless, we have shown that in this system it is necessary to
both perturb the system (intervening with stress exposure) and
block the particular agent of interest, to unravel the complexity
of the interactions in play.
Both IL-6 and TNF- were nondetectable at rest 24 h after
multiple exposures to a mild stressor, but this finding is not
inexplicable. IL-6 levels have been reported by others to
respond rapidly, rising within 15 min of exposure to psycho-
logical stress (11, 68) and to return to baseline levels within
12–24 h after exposure to acute moderate stress, albeit in other
models (48, 71). TNF- concentration is also known to be
tightly regulated, rising within 30 min of exposure to stress,
with an in vivo half-life of 2 h (16, 18, 38). In the present
study, rats were killed 24 h after the last stress exposure. Even
with chronic stress, the duration of exposure that resulted in
upregulation of basal IL-6 concentration in the circulation of
human subjects was in excess of 6 yr (30). The protocol used
in the present study was only 4 days of intermittent exposure to
a mild stressor and is not analogous to the condition of
chronically elevated circulating proinflammatory cytokines,
but rather represents a model of the early phase of adaptation
to stress. Unfortunately, because the protocol used in the present
study allowed for blood sampling at only one time point (24 h
after the last intervention), no conclusions can be made with
regard to transient changes in circulating cytokine levels.
Target Tissue Responses
The interventions used in this study did not significantly
affect total or differential WBC counts (Table 1). Absolute
Fig. 7. Comparison of gastrocnemius muscle glutamine synthetase (GS) ac-
tivity (determined by measurement of formation of -glutamylhydroxamate
from glutamate, ADP, and hydroxylamine) between the experimental groups.
prot, Protein. Values are means  SE. P values were obtained with Fisher’s
post hoc analysis.
Fig. 6. Effects of stress and/or anti-IL-6 antibody treatment on tyrosine
aminotransferase (TAT) activity (determined by the nonenzymatic conversion
of p-hydroxyphenylpyruvate to p-hydroxybenzaldehyde) in vastus muscle (A)
and liver (B) of male Wistar rats. Values are means  SE. P values were
obtained with Fisher’s post hoc analysis.
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total WBC and lymphocyte counts were slightly higher, and
the neutrophil count was lower, than those reported earlier in
Long-Evans rats subjected to either no stress or to 2 or 48 h of
social stress (63). Because these immune cell counts did not
respond to stress in either study, the differences in cell counts
between the two studies are most likely due to interstrain
differences. However, considering the reported decrease in
peripheral node lymphocyte function after acute inescapable
tail shock (17), an unchanged total WBC or lymphocyte cell
count does not necessarily imply unchanged cell function.
Therefore, functional test results should also be considered in
a comprehensive evaluation of the immune response to stress.
PBMCs in culture exhibited a similar ability to spontane-
ously secrete IL-6 during incubation in all groups. This sug-
gests that neither 4 days of immobilization stress nor short-
term blocking of IL-6 is sufficiently severe to result in a change
in basal excitation of mononuclear cells in the absence of a
specific stimulant. However, a main effect of anti-IL-6 anti-
body treatment was a significant increase in mitogen-induced
IL-6 secretion in the combined antibody-treated groups com-
pared with the combined placebo groups (main effect: P 
0.05), with no independent or interactive effect of immobili-
zation. The result of no effect of immobilization is in accor-
dance with previous reports of unchanged mitogen-induced
lymphocyte proliferation rate in rats subjected to social stress
(63). There are three possible explanations for the main effect
of the anti-IL-6 antibody. First, if the replacement of blood
plasma by culture medium in the assay procedure did not
successfully remove all of the antibody from the cell culture, it
is possible that the antibody present initially bound to the IL-6
secreted in response to LPS. This would result in an increased
cytokine secretion due to lack of early negative feedback by
IL-6 on cell function. Second, an alternative explanation is
that, if anti-IL-6 antibody became membrane bound and was
not washed out by plasma replacement, it may have prevented
negative feedback throughout the assay time period. Third,
blocking of IL-6 may have caused adaptation of PBMCs to
render them more sensitive to mitogen stimulation, so that
stimulation resulted in excess cytokine secretion by these cells.
The fact that mitogen-induced IL-6 release in vitro was posi-
tively correlated with serum IL-1 concentrations in the anti-
body-treated groups only suggests that the proposed effect on
PBMCs may have been mediated before culture by IL-1. It
also argues against the finding being an artifact of residual
antibody in the assay procedure, since the correlation was with
serum IL-1 and not with in vitro mitogen-induced PBMC-
secreted IL-1.
Chronic stress is commonly associated with body mass loss
in both human (4, 32, 73) and animal models (58). Although
the mechanisms have not been fully elucidated, either TNF-
or glucocorticoids or both may be possible mediators of this
process. Even IL-6 has recently been shown to have a direct
effect of inducing skeletal muscle atrophy by downregulation
of intracellular anabolic signaling (23). Because the present
study used intermittent immobilization to induce stress, the
possibility exists that this short duration of decreased mechan-
ical loading may have caused muscle atrophy and consequently
body mass loss. However, other studies that reported evidence
of severe disuse-induced muscle atrophy in rats used more
severe models of continuous immobilization (53, 58). The 2
h/day of immobilization in the present study occurred during
the rats’ sleep cycle and was unlikely to have altered their daily
physical activity. Rather, we present other evidence of signif-
icant glucocorticoid effects, arguing in favor of circulating
atrophy-inducing factors predominating in the observed loss of
body mass.
The finding in the present study of a 38–47% decrease in
GR levels in response to stress is in agreement with previous
reports that illustrated a stress-induced decrease of between 25
and 50% in GR levels in the liver and brain (50, 59). The GR-
binding capacities reported in the present study are lower than
those reported by other groups in the liver (e.g., 36  3
fmol/mg protein) and muscle (e.g., 6  0.5 fmol/mg protein)
(2, 67). Interstrain differences in the glucocorticoid response to
stress (5) or differences in the techniques used to determine GR
levels may explain differences in absolute binding capacities.
The IL-6 antibody treatment caused a significant downregu-
lation of GR binding capacity in both skeletal muscle and liver
in the present study, suggesting that the normal effect of IL-6
in these peripheral tissues is either an independent upregulatory
effect on GR levels or an antagonizing effect on a glucocorti-
coid-induced downregulation of its own receptors. In vitro,
IL-6 upregulates GR levels in Kaposi sarcoma (22), as well as
in lymphoid, monocytoid, and hepatoma cell lines (56). In
addition, IL-6 antibody administration has also been shown to
significantly decrease GR number in osteoblast cell lines,
abolishing the upregulatory effect of IL-6 (13). However, the
present study is the first to provide proof of this effect of IL-6
on GR levels in vivo by use of an anti-IL-6 antibody. Further-
more, the finding that GR levels are lower in the IA vs. the IP
group in both the liver and muscle, whereas corticosterone
levels are attenuated in the IA group vs. the IP group, suggests
that this effect of IL-6 is not mediated via circulating glucocor-
ticoids. We propose that future studies should investigate an
intracellular cross talk.
Increases in TAT activity after only mild stress reported in
the present study is in agreement with previous findings after
more extreme interventions, such as glucocorticoid adminis-
tration (15, 57), indicating that this enzyme is even more
sensitive to stress than previously shown. The finding reported
here of a further increase in liver TAT activity during stress, in
the anti-IL-6 antibody-treated group, suggests an inhibitory
role of IL-6 on this glucocorticoid-inducible enzyme. This
result provides in vivo support for a recent, similar finding in
rat fetal hepatoma cells in culture (74).
The nearly twofold increase in GS activity in stressed
groups, compared with their respective control groups, is in
agreement with the findings of an earlier study of intermittent
hypoxic stress in Wistar rats (69). However, the finding that GS
activity seemed to be independent of IL-6, especially given the
finding that TAT activity seemed to be directly inhibited by
IL-6 in the presence of stress, is more difficult to explain.
However, it is in line with previous studies that also failed to
show an effect of IL-6 on GS activity in murine astrocytes (10).
In conclusion, the present study illustrates that IL-6 plays a
role in modulating the effect of glucocorticoids at systemic and
peripheral levels. The present results clearly indicate that this
modulating effect is to antagonize the effects of corticosterone.
Therefore, during multiple exposures to mild stress, IL-6 plays
a role in maintenance of the IL-1 and corticosterone concen-
trations, reducing the effect of negative feedback by cortico-
sterone. In peripheral tissues, IL-6 reduces the effects of corti-
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costerone by limiting downregulation of GR levels in both
muscle and liver, as well as preventing full-blown upregulation
of activity of a glucocorticoid-inducible enzyme in the liver.
This antagonistic cross talk is reminiscent of the well-known
downregulatory effect of endogenous or exogenous glucocor-
ticoids on proinflammatory cytokines and their actions. The
authors further hypothesize that the brake provided by IL-6 in
the periphery may limit an overshoot of the deleterious endo-
crine responses of tissues to stress. This presents a finer control
of homeostasis than would be present without this dual system
of reciprocal control.
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